The vaccine is authorized for the prevention COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. The messenger RNA (mRNA)-based vaccine is administered in two doses given three weeks apart.

Clinical trial data indicated that the vaccine had an efficacy rate of 95%. The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," said Dr. Stephen Hahn, FDA commissioner.

The EUA, which is different from full FDA approval (licensure), will be effective until circumstances that justify the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 change. At this point the EUA may be revised or revoked if it is determined it no longer meets the statutory criteria for issuance.

During the December 10 VRBPAC meeting, the sponsors made it clear that they would continue collecting data for a period of two years post vaccination in all trial participants with the goal of eventually filing for full licensure with a biologics license application.

With the authorization, the companies can begin vaccine distribution in the U.S. The vaccine has already been given emergency approval in several countries, including the U.K. and Canada.

"With science guiding our decision-making, the available safety and effectiveness data support the authorization of the Pfizer-BioNTech COVID-19 vaccine because the vaccine's known and potential benefits clearly outweigh its known and potential risks," explained Dr. Peter Marks, PhD, director of the FDA's Center for Biologics Evaluation and Research.

FDA in final stages before issuing Pfizer, BioNTech EUA
The U.S. Food and Drug Administration (FDA) has informed Pfizer and BioNTech that it will work rapidly toward the finalization and issuance of an emergency...

Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy
In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results...

Reports: White House tells FDA to approve COVID-19 vaccine
The White House ordered the U.S. Food and Drug Administration (FDA) Commissioner Dr. Stephen Hahn to ensure that the FDA granted an emergency use...

FDA committee gives nod to move Pfizer, BioNTech COVID-19 vaccine toward EUA
A COVID-19 vaccine candidate from Pfizer-BioNTech, BNT162b2, passed a major milestone today when a U.S. Food and Drug Administration (FDA) advisory committee...

Health Canada approves emergency use for Pfizer, BioNTech's COVID-19 vaccine
Health Canada has granted authorization under an interim order for the emergency use of Pfizer-BioNTech's messenger RNA COVID-19 vaccine, BNT162b2.

Pfizer, BioNTech COVID-19 vaccine gets emergency approval in the U.K.
The Medicines and Healthcare Products Regulatory Agency in the U.K. has granted a temporary authorization for emergency use for BNT162b2, Pfizer and BioNTech's...